Mesoblast Ltd ADR (MESO) Stock Price, Quote & News

Company Profile

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic ref...

Industry: Biotechnology

Sector: Healthcare

Phone: 61 3 9639 6036

Fax: 61 3 9639 6030

Website: www.mesoblast.com

Address:

55 Collins Street, Level 38, Melbourne, Australia

hegdaom Jul. 17 at 8:48 PM

$CAPR $MESO

0 · Reply

mtalhambra Jul. 17 at 8:23 PM

$CAPR $CAPR $MESO Mesoblast just hit Capricor with a patent suit over Deramiocel (CAP-1002), asserting three mesenchymal-stem-cell (MSC) patents (conveniently timed ~2 weeks before the 7/29 AdCom and ~5 weeks before the 8/22 PDUFA). I went through the complaint, the asserted patents, Capricor's own '076 patent, and 9 published CDC papers, and the whole case hinges on calling Capricor's cardiosphere-derived cells "MSCs," which the science pushes back on hard: CD90 runs ~7–24% vs. the ≥ 95% needed to qualify as an MSC, the cells are cardiac in origin (not marrow), and Deramiocel's FDA-reviewed potency is anti-fibrotic, not the immunosuppression one of the patents claims. Mesoblast is also caught in a vise; read the claims broadly enough to capture CDCs and they collide with pre-2014 prior art, with the freshly issued '722 patent looking especially IPR-vulnerable.

2 · Reply

hegdaom Jul. 17 at 5:51 PM

$CAPR $MESO $XBB

0 · Reply

SendMoreTroops Jul. 17 at 5:43 PM

$CAPR it really shows something remarkable taking shape here. if data is so so terrible the way shorts now FALSELY claim, why would a multi billion company $MESO go after them? $XBB Copyright

2 · Reply

Green_Dream Jul. 17 at 4:37 PM

Mesoblast (MESO) just sued Capricor (CAPR) in Delaware to block deramiocel's launch — 3 MSC patents, injunction through 2035. Timing is everything: AdCom 7/29, PDUFA 8/22. CAPR also fighting NS Pharma, hearing 8/10. Theory: CDCs are just MSCs renamed. Proof? CAPR's own patent literally says "cardiac stem cells," and MESO quotes CAPR's own filing admitting "commercial-supply manufacturing has begun" — that kills the FDA safe harbor. Merits are close. Best count hinges on one word. Longest patent pleaded only "on information and belief." MESO may not need to win. Just needs the injunction threat credible on 8/21. And it's now a DMD competitor — so this isn't about royalties. Neither company has said a word. $CAPR $MESO

1 · Reply

Mani86 Jul. 16 at 6:16 AM

$MESO Nearing 20 dollars !!!

1 · Reply

AlertsAndNews Jul. 14 at 3:07 AM

$MESO Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain "today announced that it has achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease. The trial aims to confirm the durable pain reduction from a single intra-discal injection of rexlemestrocel-L seen in the earlier MSB-DR003 trial."

0 · Reply

Merlintrader Jul. 10 at 8:46 AM

$MESO Mesoblast ($MESO) Deep Dive: Ryoncil Hits $36M in Q4 and $115M in FY2026 https://www.merlintrader.com/mesoblast-july2026-deepdive/

1 · Reply

AlertsAndNews Jul. 10 at 2:51 AM

$MESO Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026 " today announced Ryoncil® (remestemcel-L-rknd) net revenue of US$36 million for the quarter and US$115 million for the full year ended June 30, 2026."

0 · Reply

STACKD0E Jul. 10 at 1:53 AM

$MESO ✨

0 · Reply

Mesoblast Treats 300 Patients In Phase 3 Low Back Pain Trial For Rexlemestrocel-L

Jul 13, 2026, 8:35 PM EDT - 7 days ago

Market Cap	2.24B
Revenue (ttm)	17.20M
Net Income (ttm)	-102.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-593.84%
Debt to Equity Ratio	0.22

Volume	130,936
Avg Vol	223,582
Day's Range	N/A - N/A
Shares Out	129.46M
Stochastic %K	52%
Beta	2.08
Analysts	Strong Sell
Price Target	$35.00